Latest News for KNBIF
Kane Biotech Inc. (KNE:CA) Shareholder/Analyst Call Transcript
Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane's commercial progress, clinical relevance and operational priorities
WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results.
DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiatives
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for KNBIF.
Senate Trading
No Senate trades found for KNBIF.
U.S. House Trading
No House trades found for KNBIF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.